Evidence map›Paper›PMID 40504447›Full record

ArticleAnnals of hematology2025

High-dose romiplostim for donor-type aplasia.

Kohei Hosokawa, Tatsuya Imi, Takafumi Yokota, Yuma Tada, Hiroyuki Maruyama, Naomi Sugimori, Ken Ishiyama, Hirohito Yamazaki, Toshihiro Miyamoto, Shinji Nakao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kohei HosokawaDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Ishikawa, Japan. hosokawa0814@staff.kanazawa-u.ac.jp.
Tatsuya ImiDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Ishikawa, Japan.
Takafumi YokotaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Yuma TadaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Hiroyuki MaruyamaDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Ishikawa, Japan.
Naomi SugimoriDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Ishikawa, Japan.
Ken IshiyamaDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Ishikawa, Japan.
Hirohito YamazakiDivision of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Toshihiro MiyamotoDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Ishikawa, Japan.
Shinji NakaoDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Ishikawa, Japan. snakao8205@staff.kanazawa-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Donor-type aplasia (DTA) is a severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), characterized by bone marrow hypoplasia despite full chimerism. This report highlights the successful use of romiplostim (ROMI) for treating DTA in three patients with acquired aplastic anemia (AA), including two who were unresponsive to eltrombopag (EPAG). Case 1: A 21-year-old female with non-severe AA, treated with cyclosporine (CsA), rabbit antithymocyte globulin, and EPAG, showed no improvement. After undergoing bone marrow transplantation (BMT) from an HLA-matched sibling, she continued to experience pancytopenia. Switching from EPAG to ROMI 16 months after BMT led to transfusion independence after 7 weeks and normalized blood counts by 17 months. Case 2: A 35-year-old male with moderate AA, initially treated with CsA and ROMI, switched to EPAG before BMT from an HLA-matched sibling. Despite complete donor chimerism, pancytopenia recurred 7 months after BMT. Transitioning from EPAG to ROMI resulted in transfusion independence after 5 months and normalized blood counts after 11 months of ROMI. Case 3: A 25-year-old female with moderate AA, unresponsive to CsA and EPAG, remained transfusion-dependent. Following BMT from an HLA-matched sibling and an initial lack of response to ROMI, restarting ROMI led to transfusion independence after 9 months and normalization of blood counts by day 418 post-BMT. These patients suggest ROMI, particularly at high doses, may be more effective than EPAG for DTA, potentially avoiding the need for a second allo-HSCT. Further studies are required to compare the efficacy of ROMI and EPAG in treating DTA following allo-HSCT.

Indexed as

Anemia, AplasticBone Marrow TransplantationHematopoietic Stem Cell TransplantationReceptors, FcRecombinant Fusion ProteinsThrombopoietinAdultFemaleHumansMaleTissue DonorsYoung AdultReceptors, FcRecombinant Fusion ProteinsromiplostimThrombopoietinAllo-BMTDonor-type aplasiaRomiplostim

Identifiers

PMID40504447
PMCPMC12334513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.